These observations suggested that the tumor had a SMARCA4 c.3216‐2A>G splicing variant and concomitant loss of heterozygosity (LOH) or copy‐neutral LOH, as previously reported in other SMARCA4‐deficient tumors [10]. The gene discussed is SMARCA4; the disease is neoplasm.